Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Israeli court rejects Taro's call for special tender offer by Sun

This article was originally published in Scrip

Executive Summary

A Tel Aviv court has rejected Taro Pharmaceutical Industries' contention that Sun Pharmaceutical Industriesshould have conducted a "special tender offer" under Israeli Law. This paves the way for the completion of a previously announced tender offer by Sun for all outstanding ordinary shares of Taro. Sun's tender offer for Taro follows an acrimonious dispute over a merger pact between the two companies that Taro called off in May.

You may also be interested in...



Chiesi Files India Legal Action Against Cipla Over Respiratory Therapy Patent

The Italian firm has initiated legal proceedings in India against Cipla, alleging infringement of a patent for an inhalation therapy.

Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry

Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Topics

Related Companies

UsernamePublicRestriction

Register

SC002172

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel